Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL6 | Q9H5J4 | 9/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.34 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.33 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.32 |
| ▸ | TUBB | P07437 | 1/20 | 0.32 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.32 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.32 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.32 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.32 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.32 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2470320 | 0.92 | AKR1B1 (0.33) | ELOVL6AKR1B1CYP46A1PGRIDO1 | |
| SCHEMBL2471238 | 0.90 | MAPT (0.36) | ELOVL6AKR1B1CYP46A1MAPTPGR | |
| SCHEMBL2470164 | 0.86 | AKR1B1 (0.35) | AKR1B1MAPT | |
| SCHEMBL2470294 | 0.86 | ELOVL6 (0.39) | ELOVL6AKR1B1CYP46A1ADAM10MMP1 | |
| SCHEMBL2472168 | 0.85 | ELOVL6 (0.39) | ELOVL6AKR1B1CYP46A1ADAM10MMP1 | |
| SCHEMBL2469509 | 0.84 | ADRA2C (0.32) | — | |
| SCHEMBL2469490 | 0.84 | ELOVL6 (0.38) | ELOVL6AKR1B1CYP46A1ADAM10MMP1 | |
| SCHEMBL2470807 | 0.84 | ELOVL6 (0.40) | ELOVL6AKR1B1CYP46A1ADAM10MMP1 | |
| SCHEMBL2470700 | 0.84 | CYP46A1 (0.39) | ELOVL6AKR1B1CYP46A1ADAM10MMP1 | |
| SCHEMBL2470657 | 0.83 | ELOVL6 (0.38) | ELOVL6CYP46A1ADAM10MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858520-B1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-10-05 | — | — | EP | claimed |
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK (US) | 2010-10-14 | — | — | US | claimed |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | claimed |
| EP-1858520-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2007-11-28 | — | — | EP | claimed |
| WO-2006098969-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | claimed |
| EP-1858520-B1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-1858520-B1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100210671-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. | 2010-08-19 | — | — | US | disclosed |
| US-20100210671-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. | 2010-08-19 | — | — | US | disclosed |
| WO-2009009015-A1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009009015-A1 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| EP-1858520-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006098969-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006098969-A2 | QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261741-A1 | Quinazolinone T-Type Calcium Channel Antagonists | CACNA1I, CACNA1G, CACNA1H | ELOVL6 4132/4885AKR1B1 2683/4885CYP46A1 3124/4885 |
| US-20080167329-A1 | Quinazolinone T-Type Calcium Channel Antagonists | CACNA1I, CACNA1G, CACNA1H | ELOVL6 4132/4885AKR1B1 2683/4885CYP46A1 3124/4885 |
| US-20100210671-A1 | Quinazolinone T-Type Calcium Channel Antagonists | CACNA1I, CACNA1G, CACNA1H | ELOVL6 4132/4885AKR1B1 2683/4885CYP46A1 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.